Stock NEO NEOGENOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NeoGenomics, Inc.

Equities

NEO

US64049M2098

Market Closed - Nasdaq
Other stock markets
 02:00:01 04/05/2024 am IST 		5-day change 1st Jan Change
15.3 USD +3.94% Intraday chart for NeoGenomics, Inc. +10.47% -5.44%
02/05 North American Morning Briefing : Stock Futures -3- DJ
30/04 Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating MT

Evolution of the average Target Price on NeoGenomics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

51db7cd37385e6468d35278429066.vNt7bMXUYVUxOEqzq4EOemWsSB9RGOWaEX-wh8qEqW4.8Lo-OIn5OR11WyaK3fR8CymfC1RjLojgYxvCwr6xngrvtD0OhL0vG19aeg~21c85283b9ea21f5815951f894f43e23

Analyst Recommendations on NeoGenomics, Inc.

North American Morning Briefing : Stock Futures -3- DJ
Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating MT
Piper Sandler Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Overweight Rating MT
Goldman Sachs Raises Price Target on NeoGenomics to $19 From $17, Maintains Buy Rating MT
Needham Raises NeoGenomics' Price Target to $24 From $21, Keeps Buy Rating MT
TD Cowen Cuts Price Target on NeoGenomics to $19 From $22, Maintains Outperform Rating MT
BTIG Cuts Price Target on NeoGenomics to $21 From $25, Keeps Buy Rating MT
Morgan Stanley Cuts Price Target on NeoGenomics to $16 From $18, Maintains Equal-Weight Rating MT
Goldman Sachs Cuts Price Target on NeoGenomics to $17 From $19, Maintains Buy Rating MT
BofA Securities Adjusts Price Target on NeoGenomics to $15 From $17, Maintains Neutral Rating MT
Stephens Upgrades NeoGenomics to Overweight From Equal-Weight, Price Target at $18 MT
TD Cowen Adjusts Price Target on NeoGenomics to $23 From $22, Maintains Outperform Rating MT
Benchmark Trims Price Target on NeoGenomics to $18 From $20, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on NeoGenomics to $18 From $19, Maintains Equal-Weight Rating MT
Raymond James Downgrades NeoGenomics to Market Perform From Outperform MT
Morgan Stanley Adjusts Price Target on NeoGenomics to $19 From $18, Maintains Equal-Weight Rating MT
BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $25 MT
TD Cowen Adjusts Price Target on NeoGenomics to $22 From $20, Maintains Outperform Rating MT
BofA Adjusts Price Target on NeoGenomics to $17 From $18, Keeps Neutral Rating MT
Piper Sandler Adjusts NeoGenomics' Price Target to $20 From $18, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on NeoGenomics to $18 From $17, Maintains Equal-Weight Rating MT
Raymond James Raises Price Target on NeoGenomics to $19 From $12, Maintains Outperform Rating MT
Needham Increases Price Target on NeoGenomics to $21 From $15, Maintains Buy Rating MT
Benchmark Upgrades NeoGenomics to Buy From Hold, Price Target is $20 MT
Needham Upgrades NeoGenomics to Buy From Hold, Price Target is $15 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
14.72 USD
Average target price
20.45 USD
Spread / Average Target
+38.96%
High Price Target
28 USD
Spread / Highest target
+90.22%
Low Price Target
17 USD
Spread / Lowest Target
+15.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeoGenomics, Inc.

Needham & Co.
Piper Sandler
Goldman Sachs
TD Cowen
BTIG
Morgan Stanley
BofA Securities
Stephens Inc.
Benchmark Company
Raymond James
SVB Securities LLC
SVB Leerink
Benchmark Capital
Cowen
Truist Securities

Ratings for NeoGenomics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NEO Stock
  4. Consensus NeoGenomics, Inc.